Buchumschlag

A novel Orf virus D1701-VrV-based Dengue virus (DENV) vaccine candidate expressing HLA-specific T cell epitopes: a proof-of-concept study

Although dengue virus (DENV) affects almost half of the world’s population there are neither preventive treatments nor any long-lasting and protective vaccines available at this time. The complexity of the protective immune response to DENV is still not fully understood. The most advanced vaccine ca...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Reguzova, Alena (VerfasserIn) , Fischer, Nico (VerfasserIn) , Müller, Melanie (VerfasserIn) , Salomon, Ferdinand (VerfasserIn) , Jänisch, Thomas (VerfasserIn) , Amann, Ralf (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 8 December 2021
In: Biomedicines
Year: 2021, Jahrgang: 9, Heft: 12, Pages: 1-22
ISSN:2227-9059
DOI:10.3390/biomedicines9121862
Online-Zugang:Verlag, kostenfrei, Volltext: https://doi.org/10.3390/biomedicines9121862
Verlag, kostenfrei, Volltext: https://www.mdpi.com/2227-9059/9/12/1862
Volltext
Verfasserangaben:Alena Reguzova, Nico Fischer, Melanie Müller, Ferdinand Salomon, Thomas Jaenisch, Ralf Amann

MARC

LEADER 00000caa a2200000 c 4500
001 1793844577
003 DE-627
005 20230427030933.0
007 cr uuu---uuuuu
008 220224s2021 xx |||||o 00| ||eng c
024 7 |a 10.3390/biomedicines9121862  |2 doi 
035 |a (DE-627)1793844577 
035 |a (DE-599)KXP1793844577 
035 |a (OCoLC)1341443168 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Reguzova, Alena  |e VerfasserIn  |0 (DE-588)1252495994  |0 (DE-627)1793847614  |4 aut 
245 1 2 |a A novel Orf virus D1701-VrV-based Dengue virus (DENV) vaccine candidate expressing HLA-specific T cell epitopes  |b a proof-of-concept study  |c Alena Reguzova, Nico Fischer, Melanie Müller, Ferdinand Salomon, Thomas Jaenisch, Ralf Amann 
264 1 |c 8 December 2021 
300 |a 22 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 24.02.2022 
520 |a Although dengue virus (DENV) affects almost half of the world’s population there are neither preventive treatments nor any long-lasting and protective vaccines available at this time. The complexity of the protective immune response to DENV is still not fully understood. The most advanced vaccine candidates focus specifically on humoral immune responses and the production of virus-neutralizing antibodies. However, results from several recent studies have revealed the protective role of T cells in the immune response to DENV. Hence, in this study, we generated a novel and potent DENV vaccine candidate based on an Orf virus (ORFV, genus Parapoxvirus) vector platform engineered to encode five highly conserved or cross-reactive DENV human leukocyte antigen (HLA)-A*02- or HLA-B*07-restricted epitopes as minigenes (ORFV-DENV). We showed that ORFV-DENV facilitates the in vitro priming of CD8+ T cells from healthy blood donors based on responses to each of the encoded immunogenic peptides. Moreover, we demonstrated that peripheral blood mononuclear cells isolated from clinically confirmed DENV-positive donors stimulated with ORFV-DENV generate cytotoxic T cell responses to at least three of the expressed DENV peptides. Finally, we showed that ORFV-DENV could activate CD8+ T cells isolated from donors who had recovered from Zika virus (ZIKV) infection. ZIKV belongs to the same virus family (Flaviviridae) and has epitope sequences that are homologous to those of DENV. We found that highly conserved HLA-B*07-restricted ZIKV and DENV epitopes induced functional CD8+ T cell responses in PBMCs isolated from confirmed ZIKV-positive donors. In summary, this proof-of-concept study characterizes a promising new ORFV D1701-VrV-based DENV vaccine candidate that induces broad and functional epitope-specific CD8+ T cell responses. 
650 4 |a CD8<sup>+</sup> T cells 
650 4 |a dengue virus 
650 4 |a HLA class I 
650 4 |a immune response 
650 4 |a ORFV 
650 4 |a parapoxvirus 
650 4 |a T cell epitope 
650 4 |a vaccine 
650 4 |a viral vector 
700 1 |a Fischer, Nico  |e VerfasserIn  |0 (DE-588)1225424372  |0 (DE-627)1745069488  |4 aut 
700 1 |a Müller, Melanie  |e VerfasserIn  |4 aut 
700 1 |a Salomon, Ferdinand  |e VerfasserIn  |0 (DE-588)1248663209  |0 (DE-627)1784472360  |4 aut 
700 1 |a Jänisch, Thomas  |d 1968-  |e VerfasserIn  |0 (DE-588)121170993  |0 (DE-627)705277275  |0 (DE-576)182736911  |4 aut 
700 1 |a Amann, Ralf  |d 1982-  |e VerfasserIn  |0 (DE-588)1059897067  |0 (DE-627)798977302  |0 (DE-576)416035841  |4 aut 
773 0 8 |i Enthalten in  |t Biomedicines  |d Basel : MDPI, 2013  |g 9(2021), 12, Artikel-ID 1862, Seite 1-22  |h Online-Ressource  |w (DE-627)750370483  |w (DE-600)2720867-9  |w (DE-576)384589596  |x 2227-9059  |7 nnas  |a A novel Orf virus D1701-VrV-based Dengue virus (DENV) vaccine candidate expressing HLA-specific T cell epitopes a proof-of-concept study 
773 1 8 |g volume:9  |g year:2021  |g number:12  |g elocationid:1862  |g pages:1-22  |g extent:22  |a A novel Orf virus D1701-VrV-based Dengue virus (DENV) vaccine candidate expressing HLA-specific T cell epitopes a proof-of-concept study 
856 4 0 |u https://doi.org/10.3390/biomedicines9121862  |x Verlag  |x Resolving-System  |z kostenfrei  |3 Volltext 
856 4 0 |u https://www.mdpi.com/2227-9059/9/12/1862  |x Verlag  |z kostenfrei  |3 Volltext 
951 |a AR 
992 |a 20220224 
993 |a Article 
994 |a 2021 
998 |g 121170993  |a Jänisch, Thomas  |m 121170993:Jänisch, Thomas  |d 910000  |d 912800  |d 50000  |e 910000PJ121170993  |e 912800PJ121170993  |e 50000PJ121170993  |k 0/910000/  |k 1/910000/912800/  |k 0/50000/  |p 5 
998 |g 1225424372  |a Fischer, Nico  |m 1225424372:Fischer, Nico  |d 910000  |d 911700  |e 910000PF1225424372  |e 911700PF1225424372  |k 0/910000/  |k 1/910000/911700/  |p 2 
999 |a KXP-PPN1793844577  |e 407220305X 
BIB |a Y 
SER |a journal 
JSO |a {"type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Gesehen am 24.02.2022"],"recId":"1793844577","language":["eng"],"person":[{"family":"Reguzova","given":"Alena","roleDisplay":"VerfasserIn","display":"Reguzova, Alena","role":"aut"},{"given":"Nico","family":"Fischer","role":"aut","display":"Fischer, Nico","roleDisplay":"VerfasserIn"},{"roleDisplay":"VerfasserIn","display":"Müller, Melanie","role":"aut","family":"Müller","given":"Melanie"},{"given":"Ferdinand","family":"Salomon","role":"aut","roleDisplay":"VerfasserIn","display":"Salomon, Ferdinand"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Jänisch, Thomas","given":"Thomas","family":"Jänisch"},{"family":"Amann","given":"Ralf","display":"Amann, Ralf","roleDisplay":"VerfasserIn","role":"aut"}],"title":[{"title":"A novel Orf virus D1701-VrV-based Dengue virus (DENV) vaccine candidate expressing HLA-specific T cell epitopes","subtitle":"a proof-of-concept study","title_sort":"novel Orf virus D1701-VrV-based Dengue virus (DENV) vaccine candidate expressing HLA-specific T cell epitopes"}],"physDesc":[{"extent":"22 S."}],"relHost":[{"pubHistory":["1.2013 -"],"part":{"year":"2021","pages":"1-22","issue":"12","text":"9(2021), 12, Artikel-ID 1862, Seite 1-22","volume":"9","extent":"22"},"note":["Gesehen am 12.08.20"],"type":{"media":"Online-Ressource","bibl":"periodical"},"disp":"A novel Orf virus D1701-VrV-based Dengue virus (DENV) vaccine candidate expressing HLA-specific T cell epitopes a proof-of-concept studyBiomedicines","language":["eng"],"recId":"750370483","title":[{"title_sort":"Biomedicines","title":"Biomedicines","subtitle":"open access journal"}],"physDesc":[{"extent":"Online-Ressource"}],"origin":[{"dateIssuedKey":"2013","publisher":"MDPI","dateIssuedDisp":"2013-","publisherPlace":"Basel"}],"id":{"issn":["2227-9059"],"eki":["750370483"],"zdb":["2720867-9"]}}],"name":{"displayForm":["Alena Reguzova, Nico Fischer, Melanie Müller, Ferdinand Salomon, Thomas Jaenisch, Ralf Amann"]},"origin":[{"dateIssuedDisp":"8 December 2021","dateIssuedKey":"2021"}],"id":{"doi":["10.3390/biomedicines9121862"],"eki":["1793844577"]}} 
SRT |a REGUZOVAALNOVELORFVI8202 

Ähnliche Einträge